Devyser and
The companies will work together to promote the Devyser laboratory services to support and advance research and development for pharmaceutical companies.
"We are very excited to enter into this agreement. Being able to support pharmaceutical companies' development projects to enable new and improved therapies is a part of our vision for Devyser. We are convinced that
Devyser established the US CLIA-certified laboratory during the spring of 2023 and received CLIA certification from the
The information was submitted for publication, through the agency of the contact persons below, on
For more information, please contact:
Fredrik Alpsten, CEO
Email: fredrik.alpsten@devyser.com
Telephone: +46 70 667 31 06
Email: sabina.berlin@devyser.com
Telephone: +46 73 951 95 02
About Devyser
Devyser develops, manufactures, and sells diagnostic solutions and analysis services to clinical laboratories in more than 50 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology, and transplant fields, to enable targeted cancer treatment, the diagnosis of many genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time, and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time.
Devyser was founded in 2004 and is based in
Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is
For more information, visit www.devyser.com
https://news.cision.com/devyser-diagnostics-ab/r/devyser-and-thermo-fisher-scientific-collaborate-to-promote-laboratory-services-to-advance-pharmaceu,c3834242
(c) 2023 Cision. All rights reserved., source